Day 1 - Thursday 4th May 2023
9th Market Access, Pricing & Reimbursement Global Congress 2023 Europe
Trends and Strategies to Achieve Optimum Patient Access to Healthcare
MARKET ACCESS TRENDS & STRATEGIES
- Trends that will continue to impact, Market Access, Pricing and Reimbursement in healthcare
- Unlocking data from early access
- Effective communications with internal and external stakeholders
- Embracing the digital vision
- Future trends and developments in the healthcare distribution
- Looking into increase cross-border collaboration as a potential means of controlling cost
- Addressing unfair access to medicines
- Enhancing the drive for greater price transparency
- Focus on outcomes-based reimbursement and innovative funding mechanisms
- Current trends in parallel advice: What has changed?
- Importance of seeking early regulatory, HTA, and joint consultation
- Risk and advantages of using parallel consultation at the EU or national level?
- Successful strategies to maximise the benefit of parallel consultation
Santoke Naal, Director Market Access, IGES U.K. Pharma Ltd
- New landscape for risk-sharing agreements among manufacturer, payer and patients
- Understand the benefits of a good collaboration between payers and pharma companies to ensure patient access
- What do the decision-makers on drug usage think today about how the industry is responding to the immense challenges it is facing?
- Addressing the factors that made the launch environment more challenging
- Capabilities needed for an effective drug launch
- How to best leverage outsourced partners to achieve success.
- Best practices to achieve successful commercialisation.
- Challenges and obstacles in bringing this highly complex therapies to market
- Stakeholder collaboration on the road towards a solution
- Lessons learned and applications for new entrants
- Strategies that can be taken to improve timely market access and access for patients
- The Do’s and Don’ts of contractual negotiations
- The role of real-world evidence
- How to find the right endpoints for outcome-based agreements
- Recognize the potential of Personalized Medicine in Oncology / Cancer Patients benefits;
- Identify challenges which could be encountered during HTA process;
- Develop strategies to overcome or to remove any barrier for Patient Access to Precision Oncology
- Latest legislation and impact
- Market Access at national level
- Developments at regional level
- Outlook 2023
- Overview of current considerations around orphan drug assessment
- Recent and expected trends around evolution of assessment criteria
- Anticipated impact on evaluation of orphan drugs in German
- Overall perception of orphan drug commercial opportunity due to assessment trends
- Regulatory challenges following Brexit and its effect
- Steps taken by MHRA to alleviate the effects of leaving the European regulatory network.
- Understanding the current state of pharmaceutical sector
- Addressing the priorities for negotiations
- The ability of UK citizens to access new medications
Networking Drinks Reception
